Evidence map›Paper›PMID 34300115›Full record

ArticleInternational journal of environmental research and public health2021

Phased Implementation of COVID-19 Vaccination: Rapid Assessment of Policy Adoption, Reach and Effectiveness to Protect the Most Vulnerable in the US.

Yun Li, Moming Li, Megan Rice, Yanfang Su, Chaowei Yang

Open access · goldAbstract read
In one paragraph

Article in International journal of environmental research and public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Multiple COVID-19 Waves and Vaccination Effectiveness in the United States.International journal of environmental research and public health · 2022
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Yun LiDepartment of Geography and GeoInformation Science, George Mason University, Fairfax, VA 22030, USA.ORCID 0000-0002-3205-8464
Moming LiDepartment of Epidemiology and Biostatistics, University of California at San Francisco, San Francisco, CA 94158, USA.ORCID 0000-0002-9843-8363
Megan RiceDepartment of Chemistry, Carnegie Mellon University, Pittsburgh, PA 15213, USA.ORCID 0000-0001-9600-0424
Yanfang SuDepartment of Global Health, Washington University, Seattle, WA 98195, USA.ORCID 0000-0001-7557-8518
Chaowei YangDepartment of Geography and GeoInformation Science, George Mason University, Fairfax, VA 22030, USA.ORCID 0000-0001-7768-4066
George Mason University · USCarnegie Mellon University · USUniversity of California, San Francisco · US

Funding

NSF 1835507NSF 1841520NSF 2027521
6 · The paper itself

Abstract

The US and the rest of the world have suffered from the COVID-19 pandemic for over a year. The high transmissibility and severity of this virus have provoked governments to adopt a variety of mitigation strategies. Some of these previous measures, such as social distancing and mask mandates, were effective in reducing the case growth rate yet became economically and administratively difficult to enforce as the pandemic continued. In late December 2020, COVID-19 vaccines were first approved in the US and states began a phased implementation of COVID-19 vaccination. However, there is limited quantitative evidence regarding the effectiveness of the phased COVID-19 vaccination. This study aims to provide a rapid assessment of the adoption, reach, and effectiveness of the phased implementation of COVID-19 vaccination. We utilize an event-study analysis to evaluate the effect of vaccination on the state-level daily COVID-19 case growth rate. Through this analysis, we assert that vaccination was effective in reducing the spread of COVID-19 shortly after the first shots were given. Specifically, the case growth rate declined by 0.124, 0.347, 0.345, 0.464, 0.490, and 0.756 percentage points corresponding to the 1-5, 6-10, 11-15, 16-20, 21-25, and 26 or more day periods after the initial shots. The findings could be insightful for policymakers as they work to optimize vaccine distribution in later phases, and also for the public as the COVID-19 related health risk is a contentious issue.

Indexed as

COVID-19PandemicsCOVID-19 VaccinesHumansPolicySARS-CoV-2VaccinationCOVID-19 VaccinesCOVID-19event studygrowth ratepanel regressionphased vaccination

Identifiers

PMID34300115
PMCPMC8306020
OpenAlexW3183258454

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.